top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Forte Biosciences, Inc. - Common Stock (NQ:FBRX)

44.97 +8.27 (+22.53%)
Streaming Delayed Price Updated: 1:40 PM EDT, Jul 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,170,844
Open 37.94
Bid (Size) 44.80 (100)
Ask (Size) 45.14 (200)
Prev. Close 36.70
Today's Range 37.50 - 45.36
52wk Range 9.100 - 37.58
Shares Outstanding 21,051,195
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers EUDA Health Holdings (NASDAQ:EUDA) shares rose 22.3% to $15.2 during Friday's regular session. Forte Biosciences (NASDAQ:FBRX) shares moved upwards by 18.39% to $43.45. The market value of... 
Via Benzinga
News headline image
Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable Improvement ↗
Forte Biosciences (NASDAQ:FBRX) said FB102 showed statistically significant improvement in a small placebo-controlled vitiligo study, with Chief Executive Officer Paul Wagner highlighting continued... 
Via MarketBeat

Performance

YTD
+90.5%
+90.5%
1 Month
+164.5%
+164.5%
3 Month
+32.7%
+32.7%
6 Month
+86.0%
+86.0%
1 Year
+260.3%
+260.3%

More News

Read More
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update
From Forte Biosciences, Inc.
Via Business Wire
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Forte Biosciences Announces Pricing of $150 Million Public Offering
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences Announces Proposed Public Offering
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces 2025 Results and Provides Update
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences Tops Q2 Loss Forecasts ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Forte Biosciences, Inc. Announces Results and Provides Update
From Forte Biosciences, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga

Frequently Asked Questions

Is Forte Biosciences, Inc. - Common Stock publicly traded?
Yes, Forte Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Forte Biosciences, Inc. - Common Stock trade on?
Forte Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Forte Biosciences, Inc. - Common Stock?
The ticker symbol for Forte Biosciences, Inc. - Common Stock is FBRX on the Nasdaq Stock Market
What is the current price of Forte Biosciences, Inc. - Common Stock?
The current price of Forte Biosciences, Inc. - Common Stock is 44.97
When was Forte Biosciences, Inc. - Common Stock last traded?
The last trade of Forte Biosciences, Inc. - Common Stock was at 07/10/26 01:40 PM ET
What is the market capitalization of Forte Biosciences, Inc. - Common Stock?
The market capitalization of Forte Biosciences, Inc. - Common Stock is 946.67M
How many shares of Forte Biosciences, Inc. - Common Stock are outstanding?
Forte Biosciences, Inc. - Common Stock has 947M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page